TWI460161B - １－苯基吡咯化合物 - Google Patents
１－苯基吡咯化合物 Download PDFInfo
- Publication number
- TWI460161B TWI460161B TW098134159A TW98134159A TWI460161B TW I460161 B TWI460161 B TW I460161B TW 098134159 A TW098134159 A TW 098134159A TW 98134159 A TW98134159 A TW 98134159A TW I460161 B TWI460161 B TW I460161B
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- methyl
- pyrrole
- carboxamide
- compound
- Prior art date
Links
- 150000005356 1-phenylpyrroles Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 271
- 239000000203 mixture Substances 0.000 claims description 90
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 68
- 239000003795 chemical substances by application Substances 0.000 claims description 51
- -1 2-hydroxypropyl Chemical group 0.000 claims description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 21
- 206010020772 Hypertension Diseases 0.000 claims description 21
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 21
- 208000017169 kidney disease Diseases 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 19
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 229940126585 therapeutic drug Drugs 0.000 claims description 18
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 17
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 206010019280 Heart failures Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 230000000069 prophylactic effect Effects 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 229940043274 prophylactic drug Drugs 0.000 claims description 14
- AHFINSWGYAZBOZ-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)benzaldehyde Chemical group FC(F)(F)C1=CC(Cl)=CC=C1C=O AHFINSWGYAZBOZ-UHFFFAOYSA-N 0.000 claims description 13
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 12
- 206010016654 Fibrosis Diseases 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 12
- 230000004761 fibrosis Effects 0.000 claims description 12
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 11
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 10
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 10
- 206010002383 Angina Pectoris Diseases 0.000 claims description 10
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 10
- 206010008118 cerebral infarction Diseases 0.000 claims description 10
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 206010030113 Oedema Diseases 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 8
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- FLBDMCCVBXITAO-ZDUSSCGKSA-N 1-(2,4-dichlorophenyl)-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)Cl)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 FLBDMCCVBXITAO-ZDUSSCGKSA-N 0.000 claims description 6
- QANHVYSEDAJLHZ-ZDUSSCGKSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 QANHVYSEDAJLHZ-ZDUSSCGKSA-N 0.000 claims description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- KJUMMWCOFRQVML-ZDUSSCGKSA-N 1-(2-chloro-4-fluorophenyl)-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)Cl)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 KJUMMWCOFRQVML-ZDUSSCGKSA-N 0.000 claims description 5
- YQXGVUQFXVJXSP-ZDUSSCGKSA-N 1-[4-chloro-2-(difluoromethoxy)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)OC(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 YQXGVUQFXVJXSP-ZDUSSCGKSA-N 0.000 claims description 5
- IVDMGYRTLPRBSE-ZDUSSCGKSA-N 1-[4-chloro-2-(trifluoromethoxy)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)OC(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 IVDMGYRTLPRBSE-ZDUSSCGKSA-N 0.000 claims description 5
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- DUNDTSFOUCXJOA-AWEZNQCLSA-N 1-(2-chloro-4-fluorophenyl)-2-ethyl-5-[(2s)-2-hydroxypropyl]-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CCC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(C[C@H](C)O)N1C1=CC=C(F)C=C1Cl DUNDTSFOUCXJOA-AWEZNQCLSA-N 0.000 claims description 4
- YKDRJUVCOIOBKA-ZDUSSCGKSA-N 1-[2-(difluoromethyl)-4-fluorophenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 YKDRJUVCOIOBKA-ZDUSSCGKSA-N 0.000 claims description 4
- FZPJYKNUNFUEGS-ZDUSSCGKSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 FZPJYKNUNFUEGS-ZDUSSCGKSA-N 0.000 claims description 4
- GFILFLBJFUSGFU-ZDUSSCGKSA-N 1-[4-fluoro-2-(trifluoromethoxy)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)OC(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 GFILFLBJFUSGFU-ZDUSSCGKSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- FBTPYIWUMJFLLF-NSHDSACASA-N n-(3-chloro-4-sulfamoylphenyl)-1-[4-fluoro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(N)(=O)=O)C(Cl)=C1 FBTPYIWUMJFLLF-NSHDSACASA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- AIIMYNRWFVAVON-HNNXBMFYSA-N 1-(4-chloro-2-methylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)C)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 AIIMYNRWFVAVON-HNNXBMFYSA-N 0.000 claims description 3
- PSZCHIZBNFBDFN-INIZCTEOSA-N 1-(4-fluoro-2-methylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(C)=C1 PSZCHIZBNFBDFN-INIZCTEOSA-N 0.000 claims description 3
- VTXSOQMOHSONEK-ZDUSSCGKSA-N 1-[2-(difluoromethoxy)-4-fluorophenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)OC(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 VTXSOQMOHSONEK-ZDUSSCGKSA-N 0.000 claims description 3
- LNRCOLUXWSJHNJ-CYBMUJFWSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-5-[(2r)-2-fluoropropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)C(F)(F)F)C(C[C@H](F)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 LNRCOLUXWSJHNJ-CYBMUJFWSA-N 0.000 claims description 3
- KIYWDCNTYBVXFR-ZDUSSCGKSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-sulfamoylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(N)(=O)=O)C(C)=C1 KIYWDCNTYBVXFR-ZDUSSCGKSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- MJGXNSYWRGMXJC-HNNXBMFYSA-N 1-(4-fluoro-2-methylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 MJGXNSYWRGMXJC-HNNXBMFYSA-N 0.000 claims description 2
- KCGARYQTZZSKBQ-AWEZNQCLSA-N 1-[2-(difluoromethoxy)-4-fluorophenyl]-2-ethyl-5-[(2s)-2-hydroxypropyl]-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CCC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(C[C@H](C)O)N1C1=CC=C(F)C=C1OC(F)F KCGARYQTZZSKBQ-AWEZNQCLSA-N 0.000 claims description 2
- OWWNPKCCJAMTKQ-CYBMUJFWSA-N 1-[4-chloro-2-(difluoromethoxy)phenyl]-5-[(2r)-2-fluoropropyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)OC(F)F)C(C[C@H](F)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 OWWNPKCCJAMTKQ-CYBMUJFWSA-N 0.000 claims description 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 2
- GUKPXCNCKVJPOE-UHFFFAOYSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-5-(2-hydroxyethyl)-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(CCO)N1C1=CC=C(Cl)C=C1C(F)(F)F GUKPXCNCKVJPOE-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 description 268
- 238000004128 high performance liquid chromatography Methods 0.000 description 226
- JXMQGRHLXOEQJI-UHFFFAOYSA-N ethanol;hexane;methanol Chemical compound OC.CCO.CCCCCC JXMQGRHLXOEQJI-UHFFFAOYSA-N 0.000 description 155
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 154
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 149
- 238000000132 electrospray ionisation Methods 0.000 description 148
- 238000005160 1H NMR spectroscopy Methods 0.000 description 136
- 238000004896 high resolution mass spectrometry Methods 0.000 description 83
- 239000003480 eluent Substances 0.000 description 76
- 230000000052 comparative effect Effects 0.000 description 70
- 235000019439 ethyl acetate Nutrition 0.000 description 67
- 239000000243 solution Substances 0.000 description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 238000006243 chemical reaction Methods 0.000 description 62
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 238000004587 chromatography analysis Methods 0.000 description 51
- 238000000926 separation method Methods 0.000 description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 40
- 230000002829 reductive effect Effects 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- 238000000034 method Methods 0.000 description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 28
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 229910052938 sodium sulfate Inorganic materials 0.000 description 27
- 235000011152 sodium sulphate Nutrition 0.000 description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 125000003396 thiol group Chemical class [H]S* 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical class OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 14
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- 150000001448 anilines Chemical class 0.000 description 11
- 239000007810 chemical reaction solvent Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 238000010531 catalytic reduction reaction Methods 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 9
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 238000009835 boiling Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
- RNOVGJWJVRESAA-UHFFFAOYSA-N 4-fluoro-2-(trifluoromethyl)phenol Chemical group OC1=CC=C(F)C=C1C(F)(F)F RNOVGJWJVRESAA-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 125000005594 diketone group Chemical group 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- SAVQQRYWWAGSQW-UHFFFAOYSA-N n-methyl-n-(trifluoro-$l^{4}-sulfanyl)methanamine Chemical compound CN(C)S(F)(F)F SAVQQRYWWAGSQW-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 210000002706 plastid Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- JIGQIQDNHUWUJR-UHFFFAOYSA-N 1-(4-chloro-2-methylphenyl)-5-(2-fluoroethyl)-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(CCF)N1C1=CC=C(Cl)C=C1C JIGQIQDNHUWUJR-UHFFFAOYSA-N 0.000 description 3
- ABBOJTGMRPEPDS-UHFFFAOYSA-N 1-[2-(difluoromethoxy)-4-fluorophenyl]-5-(2-fluoroethyl)-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(CCF)N1C1=CC=C(F)C=C1OC(F)F ABBOJTGMRPEPDS-UHFFFAOYSA-N 0.000 description 3
- MACHUEDVRAGBRU-UHFFFAOYSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-5-[2-(dimethylamino)-2-oxoethyl]-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)C(F)(F)F)C(CC(=O)N(C)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 MACHUEDVRAGBRU-UHFFFAOYSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012025 fluorinating agent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 150000003233 pyrroles Chemical class 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 3
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- RVRIZGVVPBNJCQ-VIFPVBQESA-N (3s)-3-phenylmethoxybutanoic acid Chemical compound OC(=O)C[C@H](C)OCC1=CC=CC=C1 RVRIZGVVPBNJCQ-VIFPVBQESA-N 0.000 description 2
- NYVMVXRWCNULRS-JTQLQIEISA-N (4s)-1-bromo-4-phenylmethoxypentan-2-one Chemical compound BrCC(=O)C[C@H](C)OCC1=CC=CC=C1 NYVMVXRWCNULRS-JTQLQIEISA-N 0.000 description 2
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical class NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- TVSNJRHKEZTDQF-UHFFFAOYSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-5-(2-hydroxyethyl)-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(CCO)N1C1=CC=C(F)C=C1C(F)(F)F TVSNJRHKEZTDQF-UHFFFAOYSA-N 0.000 description 2
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 2
- 125000006516 2-(benzyloxy)ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- DCYVFHKNXHLOAA-UHFFFAOYSA-N 2-methyl-n-(4-methylsulfonylphenyl)-1h-pyrrole-3-carboxamide Chemical compound N1C=CC(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)=C1C DCYVFHKNXHLOAA-UHFFFAOYSA-N 0.000 description 2
- LBXKTWFJTOGBAK-UHFFFAOYSA-N 4-chloro-2-(4-fluorophenoxy)-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1OC1=CC=C(F)C=C1 LBXKTWFJTOGBAK-UHFFFAOYSA-N 0.000 description 2
- JCVCFWZKJXHXIS-UHFFFAOYSA-N 4-chloro-2-(4-fluorophenyl)-1-nitrobenzene Chemical group [O-][N+](=O)C1=CC=C(Cl)C=C1C1=CC=C(F)C=C1 JCVCFWZKJXHXIS-UHFFFAOYSA-N 0.000 description 2
- WJXGYWQRHKKNIW-UHFFFAOYSA-N 4-chloro-2-(difluoromethyl)-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1C(F)F WJXGYWQRHKKNIW-UHFFFAOYSA-N 0.000 description 2
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 101000615613 Homo sapiens Mineralocorticoid receptor Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- HTBBMNGZAATEQQ-UHFFFAOYSA-N N-methoxy-1H-indol-2-amine Chemical compound CONC=1NC2=CC=CC=C2C=1 HTBBMNGZAATEQQ-UHFFFAOYSA-N 0.000 description 2
- IXVGEWBSGZXADN-JTQLQIEISA-N O[C@H](CC1=CC(=C(N1)C)C(=O)NC1=CC=C(C=C1)S(=O)(=O)C)C Chemical compound O[C@H](CC1=CC(=C(N1)C)C(=O)NC1=CC=C(C=C1)S(=O)(=O)C)C IXVGEWBSGZXADN-JTQLQIEISA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 102000054091 human NR3C2 Human genes 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- AWUPLMYXZJKHEG-UHFFFAOYSA-N methyl 2-chloro-2,2-difluoroacetate Chemical compound COC(=O)C(F)(F)Cl AWUPLMYXZJKHEG-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 150000003431 steroids Chemical group 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- DAAXEYYCKRFXRA-NSHDSACASA-N (4s)-4-phenylmethoxypentan-2-one Chemical compound CC(=O)C[C@H](C)OCC1=CC=CC=C1 DAAXEYYCKRFXRA-NSHDSACASA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HBHZSVLKXAIGCQ-AWEZNQCLSA-N 1-(2,4-dichlorophenyl)-2-ethyl-5-[(2s)-2-hydroxypropyl]-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CCC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(C[C@H](C)O)N1C1=CC=C(Cl)C=C1Cl HBHZSVLKXAIGCQ-AWEZNQCLSA-N 0.000 description 1
- JOLHQGOEQLZXOU-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-5-(2-fluoroethyl)-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(CCF)N1C1=CC=C(F)C=C1Cl JOLHQGOEQLZXOU-UHFFFAOYSA-N 0.000 description 1
- PTFKKYIXUXGZMD-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-5-(2-hydroxyethyl)-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(CCO)N1C1=CC=C(F)C=C1Cl PTFKKYIXUXGZMD-UHFFFAOYSA-N 0.000 description 1
- GLFVISSEFGHVLQ-LBPRGKRZSA-N 1-(2-chloro-4-fluorophenyl)-n-(3-chloro-4-methylsulfonylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)Cl)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(Cl)=C1 GLFVISSEFGHVLQ-LBPRGKRZSA-N 0.000 description 1
- WNZNULQAQCPNMA-NSHDSACASA-N 1-(2-chloro-4-fluorophenyl)-n-(3-chloro-4-sulfamoylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)Cl)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(N)(=O)=O)C(Cl)=C1 WNZNULQAQCPNMA-NSHDSACASA-N 0.000 description 1
- QSYGWBXFJOUJNG-LBPRGKRZSA-N 1-(2-chloro-4-fluorophenyl)-n-(3-fluoro-4-methylsulfonylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)Cl)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(F)=C1 QSYGWBXFJOUJNG-LBPRGKRZSA-N 0.000 description 1
- NRDRTOINBWTBJF-INIZCTEOSA-N 1-(2-chloro-4-methylphenyl)-2-methyl-5-[(2S)-2-phenylmethoxypropyl]pyrrole-3-carboxylic acid Chemical compound C(C1=CC=CC=C1)O[C@H](CC1=CC(=C(N1C1=C(C=C(C=C1)C)Cl)C)C(=O)O)C NRDRTOINBWTBJF-INIZCTEOSA-N 0.000 description 1
- BHVFRFVDEQEDAB-INIZCTEOSA-N 1-(4-chloro-2-methylphenyl)-2-methyl-5-[(2s)-2-phenylmethoxypropyl]pyrrole-3-carboxylic acid Chemical compound C([C@H](C)OCC=1C=CC=CC=1)C1=CC(C(O)=O)=C(C)N1C1=CC=C(Cl)C=C1C BHVFRFVDEQEDAB-INIZCTEOSA-N 0.000 description 1
- YWVAHSOEIUAMMY-HNNXBMFYSA-N 1-(4-chloro-2-methylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-sulfamoylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)C)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(N)(=O)=O)C(C)=C1 YWVAHSOEIUAMMY-HNNXBMFYSA-N 0.000 description 1
- HYMUNIYWCOEMOE-INIZCTEOSA-N 1-(4-fluoro-2-methylphenyl)-2-methyl-5-[(2s)-2-phenylmethoxypropyl]pyrrole-3-carboxylic acid Chemical compound C([C@H](C)OCC=1C=CC=CC=1)C1=CC(C(O)=O)=C(C)N1C1=CC=C(F)C=C1C HYMUNIYWCOEMOE-INIZCTEOSA-N 0.000 description 1
- PCPHXHCRLUWSGF-INIZCTEOSA-N 1-[2-(difluoromethoxy)-4-fluorophenyl]-2-ethyl-5-[(2S)-2-phenylmethoxypropyl]pyrrole Chemical compound C(C1=CC=CC=C1)O[C@H](CC1=CC=C(N1C1=C(C=C(C=C1)F)OC(F)F)CC)C PCPHXHCRLUWSGF-INIZCTEOSA-N 0.000 description 1
- HPFFIMZPJPWJIO-AWEZNQCLSA-N 1-[2-(difluoromethoxy)-4-fluorophenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)OC(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(C)=C1 HPFFIMZPJPWJIO-AWEZNQCLSA-N 0.000 description 1
- XHRVPMTUOBTMJB-LBPRGKRZSA-N 1-[2-(difluoromethoxy)-4-fluorophenyl]-n-(3-fluoro-4-methylsulfonylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)OC(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(F)=C1 XHRVPMTUOBTMJB-LBPRGKRZSA-N 0.000 description 1
- FWBMPGMQHABLEX-AWEZNQCLSA-N 1-[2-(difluoromethyl)-4-fluorophenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(C)=C1 FWBMPGMQHABLEX-AWEZNQCLSA-N 0.000 description 1
- WRDUIAPNIPDCLZ-LBPRGKRZSA-N 1-[2-(difluoromethyl)-4-fluorophenyl]-n-(3-fluoro-4-methylsulfonylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(F)=C1 WRDUIAPNIPDCLZ-LBPRGKRZSA-N 0.000 description 1
- GJCYPZGWSQSUIB-AWEZNQCLSA-N 1-[4-chloro-2-(trifluoromethoxy)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)OC(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(C)=C1 GJCYPZGWSQSUIB-AWEZNQCLSA-N 0.000 description 1
- SLCZWFMAAGTJFH-IBGZPJMESA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-2-methyl-n-(4-methylsulfonylphenyl)-5-[(2s)-2-phenylmethoxypropyl]pyrrole-3-carboxamide Chemical compound C([C@H](C)OCC=1C=CC=CC=1)C(N(C=1C)C=2C(=CC(Cl)=CC=2)C(F)(F)F)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 SLCZWFMAAGTJFH-IBGZPJMESA-N 0.000 description 1
- GSAYHGKIZFLKFN-UHFFFAOYSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-5-(2-fluoroethyl)-2-methyl-n-(4-sulfamoylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(N)(=O)=O)C=C(CCF)N1C1=CC=C(Cl)C=C1C(F)(F)F GSAYHGKIZFLKFN-UHFFFAOYSA-N 0.000 description 1
- DYRIBBSWDUZYHM-AWEZNQCLSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(C)=C1 DYRIBBSWDUZYHM-AWEZNQCLSA-N 0.000 description 1
- GTKBKTKZKUNTSH-ZDUSSCGKSA-N 1-[4-chloro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-sulfamoylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(N)(=O)=O)C(C)=C1 GTKBKTKZKUNTSH-ZDUSSCGKSA-N 0.000 description 1
- JCVRBJJGSYPXMA-UHFFFAOYSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)(F)F)C(C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 JCVRBJJGSYPXMA-UHFFFAOYSA-N 0.000 description 1
- YUPJWVANSBJADI-UHFFFAOYSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-5-(2-phenylmethoxyethyl)pyrrole-3-carboxylic acid Chemical compound C(C1=CC=CC=C1)OCCC1=CC(=C(N1C1=C(C=C(C=C1)F)C(F)(F)F)C)C(=O)O YUPJWVANSBJADI-UHFFFAOYSA-N 0.000 description 1
- LEYHWPVYHMPCEZ-UHFFFAOYSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-n-(4-methylsulfonylphenyl)-5-(2-phenylmethoxyethyl)pyrrole-3-carboxamide Chemical compound C=1C=C(F)C=C(C(F)(F)F)C=1N1C(C)=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C1CCOCC1=CC=CC=C1 LEYHWPVYHMPCEZ-UHFFFAOYSA-N 0.000 description 1
- AWQQIVFSGDEBEJ-AWEZNQCLSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methyl-n-(3-methyl-4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(C)=C1 AWQQIVFSGDEBEJ-AWEZNQCLSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- AUKDFDQPJWJEDH-UHFFFAOYSA-N 1-fluoro-3-(trifluoromethoxy)benzene Chemical compound FC1=CC=CC(OC(F)(F)F)=C1 AUKDFDQPJWJEDH-UHFFFAOYSA-N 0.000 description 1
- KGNQDBQYEBMPFZ-UHFFFAOYSA-N 1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1 KGNQDBQYEBMPFZ-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- PMFKZXDQJUKLPR-UHFFFAOYSA-N 1-methyl-N-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CN1C=C(C=C1)C(=O)NC1=CC=C(C=C1)S(=O)(=O)C PMFKZXDQJUKLPR-UHFFFAOYSA-N 0.000 description 1
- AKWIAIDKXNKXDI-UHFFFAOYSA-N 1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- IANXAXNUNBAWBA-UHFFFAOYSA-N 2,2,3-trimethylundecane Chemical compound CCCCCCCCC(C)C(C)(C)C IANXAXNUNBAWBA-UHFFFAOYSA-N 0.000 description 1
- ZVZMBGQCIYWPBE-UHFFFAOYSA-N 2-(difluoromethoxy)-4-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1OC(F)F ZVZMBGQCIYWPBE-UHFFFAOYSA-N 0.000 description 1
- YNDSRZNRALJMIX-UHFFFAOYSA-N 2-(difluoromethoxy)-4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1OC(F)F YNDSRZNRALJMIX-UHFFFAOYSA-N 0.000 description 1
- ADBUIWGABVQONJ-UHFFFAOYSA-N 2-(difluoromethyl)-4-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1C(F)F ADBUIWGABVQONJ-UHFFFAOYSA-N 0.000 description 1
- GMOKYLWICVYFLS-UHFFFAOYSA-N 2-(difluoromethyl)-4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1C(F)F GMOKYLWICVYFLS-UHFFFAOYSA-N 0.000 description 1
- QENSPHDMUCKFCL-UHFFFAOYSA-N 2-methyl-n-(4-methylsulfonylphenyl)-5-(2-phenylmethoxyethyl)-1-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1N1C(C)=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C1CCOCC1=CC=CC=C1 QENSPHDMUCKFCL-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- VBEZMRJLMPYKBT-UHFFFAOYSA-N 3-chloro-4-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C=C1Cl VBEZMRJLMPYKBT-UHFFFAOYSA-N 0.000 description 1
- UZFFABPIOVUPIK-UHFFFAOYSA-N 3-ethyl-1h-indol-2-amine Chemical compound C1=CC=C2C(CC)=C(N)NC2=C1 UZFFABPIOVUPIK-UHFFFAOYSA-N 0.000 description 1
- WSARYNAINPBAEY-UHFFFAOYSA-N 3-fluoro-4-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C=C1F WSARYNAINPBAEY-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- XJSGKXZRGAIREF-UHFFFAOYSA-N 3-methyl-4-methylsulfonylaniline Chemical compound CC1=CC(N)=CC=C1S(C)(=O)=O XJSGKXZRGAIREF-UHFFFAOYSA-N 0.000 description 1
- PPGSUPFDLFLUAL-UHFFFAOYSA-N 4-amino-2-methylbenzenesulfonamide Chemical compound CC1=CC(N)=CC=C1S(N)(=O)=O PPGSUPFDLFLUAL-UHFFFAOYSA-N 0.000 description 1
- YKTYTEBUEPLEHW-UHFFFAOYSA-N 4-chloro-2-(4-fluorophenoxy)aniline Chemical compound NC1=CC=C(Cl)C=C1OC1=CC=C(F)C=C1 YKTYTEBUEPLEHW-UHFFFAOYSA-N 0.000 description 1
- DCJWZLPHRSFAMS-UHFFFAOYSA-N 4-chloro-2-(4-fluorophenyl)aniline Chemical compound NC1=CC=C(Cl)C=C1C1=CC=C(F)C=C1 DCJWZLPHRSFAMS-UHFFFAOYSA-N 0.000 description 1
- BYUMXSZWNJWOAQ-UHFFFAOYSA-N 4-chloro-2-(difluoromethyl)aniline Chemical compound NC1=CC=C(Cl)C=C1C(F)F BYUMXSZWNJWOAQ-UHFFFAOYSA-N 0.000 description 1
- CVINWVPRKDIGLL-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)aniline Chemical compound NC1=CC=C(Cl)C=C1C(F)(F)F CVINWVPRKDIGLL-UHFFFAOYSA-N 0.000 description 1
- PTCPUGKKWNMITF-UHFFFAOYSA-N 4-chloro-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1F PTCPUGKKWNMITF-UHFFFAOYSA-N 0.000 description 1
- VBATUITURYFZIU-UHFFFAOYSA-N 4-fluoro-1-nitro-2-(trifluoromethoxy)benzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1OC(F)(F)F VBATUITURYFZIU-UHFFFAOYSA-N 0.000 description 1
- QFDKCJQODJFZID-UHFFFAOYSA-N 4-fluoro-2-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(F)C=C1OC(F)(F)F QFDKCJQODJFZID-UHFFFAOYSA-N 0.000 description 1
- LRCQLCWUUBSUOY-UHFFFAOYSA-N 4-fluoro-2-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C=C1C(F)(F)F LRCQLCWUUBSUOY-UHFFFAOYSA-N 0.000 description 1
- KMHLGVTVACLEJE-UHFFFAOYSA-N 4-fluoro-2-methylaniline Chemical compound CC1=CC(F)=CC=C1N KMHLGVTVACLEJE-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- XJEVFFNOMKXBLU-UHFFFAOYSA-N 4-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C=C1 XJEVFFNOMKXBLU-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-M 4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-M 0.000 description 1
- BTOZGSIVAZGXCH-UHFFFAOYSA-N 4-phenylmethoxybutan-2-one Chemical compound CC(=O)CCOCC1=CC=CC=C1 BTOZGSIVAZGXCH-UHFFFAOYSA-N 0.000 description 1
- MNCLXPGQIRJWKU-UHFFFAOYSA-N 5-(2-fluoroethyl)-1-(4-fluoro-2-methylphenyl)-2-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(CCF)N1C1=CC=C(F)C=C1C MNCLXPGQIRJWKU-UHFFFAOYSA-N 0.000 description 1
- CZLINIUABLILIK-UHFFFAOYSA-N 5-(2-fluoroethyl)-1-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methyl-n-(4-sulfamoylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(N)(=O)=O)C=C(CCF)N1C1=CC=C(F)C=C1C(F)(F)F CZLINIUABLILIK-UHFFFAOYSA-N 0.000 description 1
- UBIRAMKOIYMUFQ-UHFFFAOYSA-N 5-(2-hydroxyethyl)-2-methyl-n-(4-methylsulfonylphenyl)-1-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)C=C(CCO)N1C1=CC=CC=C1C(F)(F)F UBIRAMKOIYMUFQ-UHFFFAOYSA-N 0.000 description 1
- SWGPIDCNYAYXMJ-UHFFFAOYSA-N 5-chloro-2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1C=O SWGPIDCNYAYXMJ-UHFFFAOYSA-N 0.000 description 1
- KKAFVHUJZPVWND-UHFFFAOYSA-N 5-fluoro-2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1C=O KKAFVHUJZPVWND-UHFFFAOYSA-N 0.000 description 1
- QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- OPBDMRAZDGNPOM-LBAUFKAWSA-N C(C)OC(C(CC(C[C@H](C)OCC1=CC=CC=C1)=O)C=C)=O Chemical compound C(C)OC(C(CC(C[C@H](C)OCC1=CC=CC=C1)=O)C=C)=O OPBDMRAZDGNPOM-LBAUFKAWSA-N 0.000 description 1
- XYHNCZPHZNWYPV-LBAUFKAWSA-N C(C)OC(C(CC(C[C@H](C)OCC1=CC=CC=C1)=O)CC)=O Chemical compound C(C)OC(C(CC(C[C@H](C)OCC1=CC=CC=C1)=O)CC)=O XYHNCZPHZNWYPV-LBAUFKAWSA-N 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- UGTULCFYGWWBGH-VKGTZQKMSA-N ClC1=CC(=C(C=C1)N1C(=C(C=C1C[C@H](C)O)C(=O)NC1=CC=C(C=C1)C([C@@H](N)CCSC)=O)C)OC1=CC=C(C=C1)F Chemical compound ClC1=CC(=C(C=C1)N1C(=C(C=C1C[C@H](C)O)C(=O)NC1=CC=C(C=C1)C([C@@H](N)CCSC)=O)C)OC1=CC=C(C=C1)F UGTULCFYGWWBGH-VKGTZQKMSA-N 0.000 description 1
- LNRUBSYRNKVECQ-UHFFFAOYSA-N ClC=1C=C(C=CC1S(=O)(=O)C=1NC2=CC=CC=C2C1)NC(C)=O Chemical compound ClC=1C=C(C=CC1S(=O)(=O)C=1NC2=CC=CC=C2C1)NC(C)=O LNRUBSYRNKVECQ-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014664 Endocardial fibrosis Diseases 0.000 description 1
- VBTBZQQJEBPBNN-UHFFFAOYSA-N FC=1C=C(C=CC1S(=O)(=O)C=1NC2=CC=CC=C2C1)NC(C)=O Chemical compound FC=1C=C(C=CC1S(=O)(=O)C=1NC2=CC=CC=C2C1)NC(C)=O VBTBZQQJEBPBNN-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229940123502 Hormone receptor antagonist Drugs 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- NFYJRKASGKXBAQ-SBUREZEXSA-N N-[4-[(2S)-2-amino-4-methylsulfanylbutanoyl]phenyl]-1-[2-(difluoromethoxy)-4-methylphenyl]-5-[(2S)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound FC(OC1=C(C=CC(=C1)C)N1C(=C(C=C1C[C@H](C)O)C(=O)NC1=CC=C(C=C1)C([C@@H](N)CCSC)=O)C)F NFYJRKASGKXBAQ-SBUREZEXSA-N 0.000 description 1
- REZXJNLEHZXZBZ-UHFFFAOYSA-N N1C(=CC2=CC=CC=C12)C1=C(C=C(C=C1)NC(C)=O)C Chemical compound N1C(=CC2=CC=CC=C12)C1=C(C=C(C=C1)NC(C)=O)C REZXJNLEHZXZBZ-UHFFFAOYSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- JLCHNBRGUPQWKF-UHFFFAOYSA-J [OH-].[C+4].[OH-].[OH-].[OH-] Chemical compound [OH-].[C+4].[OH-].[OH-].[OH-] JLCHNBRGUPQWKF-UHFFFAOYSA-J 0.000 description 1
- NFYPHBBDAHQEJU-UHFFFAOYSA-N acetonitrile;phthalic acid Chemical compound CC#N.OC(=O)C1=CC=CC=C1C(O)=O NFYPHBBDAHQEJU-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- PHSMPGGNMIPKTH-UHFFFAOYSA-K cerium(3+);trifluoromethanesulfonate Chemical compound [Ce+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F PHSMPGGNMIPKTH-UHFFFAOYSA-K 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- 150000001804 chlorine Chemical class 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XLQDQRMFMXYSQS-UHFFFAOYSA-N dichloromethane;hydrochloride Chemical compound Cl.ClCCl XLQDQRMFMXYSQS-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- NMFZRKUPBIYKQK-NBFOIZRFSA-N ethyl (3s)-2-ethyl-3-phenylmethoxybutanoate Chemical compound CCOC(=O)C(CC)[C@H](C)OCC1=CC=CC=C1 NMFZRKUPBIYKQK-NBFOIZRFSA-N 0.000 description 1
- OMSUIQOIVADKIM-YFKPBYRVSA-N ethyl (3s)-3-hydroxybutanoate Chemical compound CCOC(=O)C[C@H](C)O OMSUIQOIVADKIM-YFKPBYRVSA-N 0.000 description 1
- WTTFJVXRZAOWQO-NSHDSACASA-N ethyl (3s)-3-phenylmethoxybutanoate Chemical compound CCOC(=O)C[C@H](C)OCC1=CC=CC=C1 WTTFJVXRZAOWQO-NSHDSACASA-N 0.000 description 1
- WIXOIUKHZYKIPR-UHFFFAOYSA-N ethyl 1-(4-fluoro-2-methylphenyl)-2-methyl-5-(2-phenylmethoxyethyl)pyrrole-3-carboxylate Chemical compound C=1C=C(F)C=C(C)C=1N1C(C)=C(C(=O)OCC)C=C1CCOCC1=CC=CC=C1 WIXOIUKHZYKIPR-UHFFFAOYSA-N 0.000 description 1
- ICJYWDHNTMJKFP-UHFFFAOYSA-N ethyl 1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=CNC=1 ICJYWDHNTMJKFP-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ATBKVKDEMSGMTQ-UHFFFAOYSA-N hydrazine triphenylphosphane Chemical compound NN.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1 ATBKVKDEMSGMTQ-UHFFFAOYSA-N 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- RPRUGWCIZXCIRS-FQEVSTJZSA-N n-(3-chloro-4-methylsulfonylphenyl)-1-(4-fluoro-2-methylphenyl)-2-methyl-5-[(2s)-2-phenylmethoxypropyl]pyrrole-3-carboxamide Chemical compound C([C@H](C)OCC=1C=CC=CC=1)C(N(C=1C)C=2C(=CC(F)=CC=2)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(Cl)=C1 RPRUGWCIZXCIRS-FQEVSTJZSA-N 0.000 description 1
- ZHFPXJKQJAAVGV-AWEZNQCLSA-N n-(3-chloro-4-methylsulfonylphenyl)-1-(4-fluoro-2-methylphenyl)-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(Cl)=C1 ZHFPXJKQJAAVGV-AWEZNQCLSA-N 0.000 description 1
- PGORMRWQGBWJCN-LBPRGKRZSA-N n-(3-chloro-4-methylsulfonylphenyl)-1-[2-(difluoromethoxy)-4-fluorophenyl]-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)OC(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(Cl)=C1 PGORMRWQGBWJCN-LBPRGKRZSA-N 0.000 description 1
- VNYFDEUVZNUBFY-UHFFFAOYSA-N n-(3-chloro-4-methylsulfonylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(S(C)(=O)=O)C(Cl)=C1 VNYFDEUVZNUBFY-UHFFFAOYSA-N 0.000 description 1
- GTICJIREZPHVJA-NSHDSACASA-N n-(3-chloro-4-sulfamoylphenyl)-1-[4-chloro-2-(trifluoromethoxy)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)OC(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(N)(=O)=O)C(Cl)=C1 GTICJIREZPHVJA-NSHDSACASA-N 0.000 description 1
- RJTWRYWUAYFQSU-NSHDSACASA-N n-(3-chloro-4-sulfamoylphenyl)-1-[4-chloro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(Cl)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(N)(=O)=O)C(Cl)=C1 RJTWRYWUAYFQSU-NSHDSACASA-N 0.000 description 1
- RHUJVFXXRUFUJD-NSHDSACASA-N n-(3-chloro-4-sulfamoylphenyl)-1-[4-fluoro-2-(trifluoromethoxy)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)OC(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(N)(=O)=O)C(Cl)=C1 RHUJVFXXRUFUJD-NSHDSACASA-N 0.000 description 1
- MOWGYJQPOWBROJ-LBPRGKRZSA-N n-(3-fluoro-4-methylsulfonylphenyl)-1-[4-fluoro-2-(trifluoromethyl)phenyl]-5-[(2s)-2-hydroxypropyl]-2-methylpyrrole-3-carboxamide Chemical compound CC=1N(C=2C(=CC(F)=CC=2)C(F)(F)F)C(C[C@@H](O)C)=CC=1C(=O)NC1=CC=C(S(C)(=O)=O)C(F)=C1 MOWGYJQPOWBROJ-LBPRGKRZSA-N 0.000 description 1
- WZFPCYGNIIMWLN-UHFFFAOYSA-N n-(3-fluoro-4-methylsulfonylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(S(C)(=O)=O)C(F)=C1 WZFPCYGNIIMWLN-UHFFFAOYSA-N 0.000 description 1
- SJYDMRYFPWUZSY-UHFFFAOYSA-N n-(3-methyl-4-methylsulfonylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(S(C)(=O)=O)C(C)=C1 SJYDMRYFPWUZSY-UHFFFAOYSA-N 0.000 description 1
- WNBDFGKOXHRFIU-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC(=O)C1=CNC=C1 WNBDFGKOXHRFIU-UHFFFAOYSA-N 0.000 description 1
- IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/42—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10380408P | 2008-10-08 | 2008-10-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201028376A TW201028376A (en) | 2010-08-01 |
| TWI460161B true TWI460161B (zh) | 2014-11-11 |
Family
ID=41328965
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW098134159A TWI460161B (zh) | 2008-10-08 | 2009-10-08 | １－苯基吡咯化合物 |
| TW103129290A TWI532717B (zh) | 2008-10-08 | 2009-10-08 | １-苯基吡咯化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103129290A TWI532717B (zh) | 2008-10-08 | 2009-10-08 | １-苯基吡咯化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8642640B2 (enExample) |
| EP (1) | EP2349996B1 (enExample) |
| JP (2) | JP5767587B2 (enExample) |
| KR (1) | KR101671868B1 (enExample) |
| CN (1) | CN102177137B (enExample) |
| AU (1) | AU2009302375B2 (enExample) |
| BR (1) | BRPI0920551B1 (enExample) |
| CA (1) | CA2736930C (enExample) |
| ES (1) | ES2453500T3 (enExample) |
| IL (1) | IL212171A (enExample) |
| TW (2) | TWI460161B (enExample) |
| WO (1) | WO2010042626A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102177137B (zh) * | 2008-10-08 | 2015-03-18 | 埃克塞利希斯股份有限公司 | 1-苯基吡咯化合物 |
| CN104478782B (zh) * | 2015-01-13 | 2016-03-16 | 佛山市赛维斯医药科技有限公司 | 一类含烷氧苯基和二烯氟代金刚烷结构的化合物和用途 |
| CN104447484B (zh) * | 2015-01-13 | 2016-06-08 | 佛山市赛维斯医药科技有限公司 | 含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途 |
| CN104447485A (zh) * | 2015-01-13 | 2015-03-25 | 佛山市赛维斯医药科技有限公司 | 一种含腈基苯和二烯金刚烷结构的化合物、其制备方法和用途 |
| CN104478781A (zh) * | 2015-01-13 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 二烯金刚烷类化合物、其制备方法和用途 |
| AU2020371836B2 (en) | 2019-10-25 | 2026-01-29 | Sunshine Lake Pharma Co., Ltd. | Pyrrole amide compound and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012642A2 (en) * | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI444185B (zh) | 2007-04-09 | 2014-07-11 | Daiichi Sankyo Co Ltd | 吡咯衍生物之阻轉異構物 |
| CN102177137B (zh) * | 2008-10-08 | 2015-03-18 | 埃克塞利希斯股份有限公司 | 1-苯基吡咯化合物 |
-
2009
- 2009-10-07 CN CN200980139825.9A patent/CN102177137B/zh active Active
- 2009-10-07 WO PCT/US2009/059852 patent/WO2010042626A1/en not_active Ceased
- 2009-10-07 JP JP2011531142A patent/JP5767587B2/ja active Active
- 2009-10-07 KR KR1020117010429A patent/KR101671868B1/ko not_active Expired - Fee Related
- 2009-10-07 BR BRPI0920551-9A patent/BRPI0920551B1/pt active IP Right Grant
- 2009-10-07 EP EP09793339.4A patent/EP2349996B1/en active Active
- 2009-10-07 ES ES09793339.4T patent/ES2453500T3/es active Active
- 2009-10-07 AU AU2009302375A patent/AU2009302375B2/en not_active Ceased
- 2009-10-07 US US13/122,239 patent/US8642640B2/en active Active
- 2009-10-07 CA CA2736930A patent/CA2736930C/en active Active
- 2009-10-08 TW TW098134159A patent/TWI460161B/zh active
- 2009-10-08 TW TW103129290A patent/TWI532717B/zh active
-
2011
- 2011-04-06 IL IL212171A patent/IL212171A/en active IP Right Grant
-
2014
- 2014-07-22 JP JP2014148863A patent/JP5837655B2/ja not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012642A2 (en) * | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102177137B (zh) | 2015-03-18 |
| JP5767587B2 (ja) | 2015-08-19 |
| HK1155162A1 (en) | 2012-05-11 |
| IL212171A0 (en) | 2011-06-30 |
| CN102177137A (zh) | 2011-09-07 |
| CA2736930A1 (en) | 2010-04-15 |
| TWI532717B (zh) | 2016-05-11 |
| EP2349996A1 (en) | 2011-08-03 |
| BRPI0920551B1 (pt) | 2021-12-14 |
| CA2736930C (en) | 2016-11-22 |
| JP2014196366A (ja) | 2014-10-16 |
| JP2012505226A (ja) | 2012-03-01 |
| TW201028376A (en) | 2010-08-01 |
| TW201514144A (zh) | 2015-04-16 |
| JP5837655B2 (ja) | 2015-12-24 |
| US8642640B2 (en) | 2014-02-04 |
| US20110263544A1 (en) | 2011-10-27 |
| AU2009302375A1 (en) | 2010-04-15 |
| WO2010042626A1 (en) | 2010-04-15 |
| KR20110091664A (ko) | 2011-08-12 |
| ES2453500T3 (es) | 2014-04-08 |
| BRPI0920551A2 (pt) | 2020-08-11 |
| EP2349996B1 (en) | 2014-01-01 |
| KR101671868B1 (ko) | 2016-11-03 |
| IL212171A (en) | 2015-11-30 |
| AU2009302375B2 (en) | 2015-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101679243B (zh) | 吡咯衍生物的阻转异构体 | |
| TWI532717B (zh) | １-苯基吡咯化合物 | |
| US20080275043A1 (en) | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | |
| JP2009534471A (ja) | １１−β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロヘキシル置換ピロリジノン | |
| CN1980894A (zh) | 作为ppar调节剂的化合物和组合物 | |
| JP5767586B2 (ja) | （ヒドロキシアルキル）ピロール誘導体のアトロプ異性体 | |
| US7365069B2 (en) | Pyrimidone derivatives | |
| JP2010111657A (ja) | ピロール誘導体のアトロプ異性体を含有する医薬 | |
| HK1155162B (en) | 1-phenylpyrrole compounds | |
| CN101189231B (zh) | 环状氨基苯基链烷酸衍生物 | |
| JPH0457669B2 (enExample) |